GO:0070449 elongin complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070449 (elongin complex) is a transcription elongation factor complex that suppresses RNA polymerase II pausing and consists of Elongin A, Elongin B, and Elongin C subunits.
• The elongin complex is best known as the substrate-recognition module of Cullin-RING E3 ubiquitin ligases, where Elongin C binds BC-box proteins such as VHL, SOCS2, and AXL.
• Cryo-EM and biochemical studies show that Elongin A directly engages transcribing RNA polymerase II, linking the complex to co-transcriptional regulation.
• The Elongin BC complex negatively regulates AXL and marks a differentiated phenotype in melanoma, making it relevant to cancer biology.
• SOCS2 uses the elongin BC scaffold to ubiquitinate SLC7A11, promoting ferroptosis and radiosensitization in hepatocellular carcinoma.
• The elongin complex is a validated target for PROTAC design, as shown by structural studies of cooperative recognition for selective protein degradation.
Description
The elongin complex (GO:0070449) is a cellular component defined as a transcription elongation factor complex that suppresses RNA polymerase II pausing and may act by promoting proper alignment of the 3'-end of nascent transcripts with the polymerase catalytic site. It consists of a transcriptionally active Elongin A subunit of about 100 kDa and two smaller subunits, Elongin B (about 18 kDa) and Elongin C (about 15 kDa). This complex is conserved and has been studied for decades as both a regulator of transcription elongation and a central adaptor for ubiquitin-mediated proteolysis. Researchers care about GO:0070449 because it sits at the intersection of RNA polymerase II control, protein degradation, and human disease, including clear-cell renal cell carcinoma and melanoma. The Elongin BC subcomplex in particular serves as a hub that recruits BC-box proteins to Cullin-RING ligases, a principle now exploited in PROTAC drug design. Understanding the elongin complex therefore informs transcription biology, cancer genetics, and therapeutic development.
elongin complex At A Glance
| GO ID | GO:0070449 |
|---|---|
| GO term | elongin complex |
| Ontology | cellular_component |
| Synonym | elongin (SIII) complex; transcription elongation factor SIII complex; transcription factor B (SIII) complex |
| Major function | Suppresses RNA polymerase II pausing and promotes proper alignment of the 3'-end of nascent transcripts with the polymerase catalytic site |
| Subunit composition | Elongin A (~100 kDa), Elongin B (~18 kDa), Elongin C (~15 kDa) |
| Related complex | Elongin BC subcomplex acts as a substrate-recognition module for Cullin-RING E3 ubiquitin ligases |
| Disease links | Clear-cell renal cell carcinoma, melanoma, hepatocellular carcinoma |
| Therapeutic relevance | Targeted by PROTACs that recruit Elongin BC for selective protein degradation |
What Is GO:0070449?
In simple terms, the elongin complex is a three-protein machine that helps RNA polymerase II transcribe genes efficiently and also acts as a docking platform for proteins that need to be tagged for degradation. According to the QuickGO definition, GO:0070449 is a transcription elongation factor complex that suppresses RNA polymerase II pausing and may act by promoting proper alignment of the 3'-end of nascent transcripts with the polymerase catalytic site. It consists of a transcriptionally active Elongin A subunit (about 100 kDa) and two smaller Elongin B (about 18 kDa) and Elongin C (about 15 kDa) subunits. Synonyms include elongin (SIII) complex, transcription elongation factor SIII complex, and transcription factor B (SIII) complex.
Why Is elongin complex Important in Cell Biology?
The elongin complex is important because it couples transcription elongation with protein degradation and is directly implicated in major human cancers. Its Elongin BC subcomplex is the obligate partner for the von Hippel-Lindau tumor suppressor protein, and disruption of this interaction is a hallmark of clear-cell renal cell carcinoma. In melanoma, the Elongin BC complex negatively regulates AXL and marks a differentiated phenotype, linking it to tumor progression and therapy resistance. In hepatocellular carcinoma, SOCS2-enhanced ubiquitination of SLC7A11 depends on the elongin BC scaffold and promotes ferroptosis and radiosensitization. Beyond cancer, the elongin complex is a structural paradigm for PROTAC-induced cooperative recognition, making it a central node in chemical biology and drug discovery. It also participates in diverse cellular functions through multiple BC-box proteins, as reviewed in early biochemical studies.
• Suppresses RNA polymerase II pausing and supports productive transcription elongation.
• Serves as the substrate-recognition module for Cullin-RING E3 ubiquitin ligases via Elongin C.
• Binds the von Hippel-Lindau tumor suppressor protein, linking it to clear-cell renal cell carcinoma.
• Negatively regulates AXL and marks a differentiated phenotype in melanoma.
• Enables SOCS2-mediated ubiquitination of SLC7A11, promoting ferroptosis and radiosensitization in hepatocellular carcinoma.
• Provides the structural basis for PROTAC cooperative recognition and selective protein degradation.
• Regulates multiple cellular functions through diverse BC-box proteins.
• Is conserved across metazoans and studied as a model of transcription elongation control.
• Offers a druggable interface for targeted protein degradation therapeutics.
• Connects transcription elongation, ubiquitin signaling, and cancer biology in one complex.
What Happens During elongin complex?
Transcription elongation and pausing suppression
In simple terms: The elongin complex helps RNA polymerase II keep moving instead of stalling during gene transcription.
The elongin complex is defined as a transcription elongation factor complex that suppresses RNA polymerase II pausing and may act by promoting proper alignment of the 3'-end of nascent transcripts with the polymerase catalytic site. Structural analysis of the transcribing RNA polymerase II-Elongin complex shows how Elongin A engages the polymerase to support processive elongation. This function places GO:0070449 among the cellular components that directly modulate the elongation phase of transcription.
Assembly of the Elongin BC subcomplex
In simple terms: Elongin B and Elongin C pair up to form a stable scaffold that other proteins can bind.
The elongin complex consists of a transcriptionally active Elongin A subunit (about 100 kDa) and two smaller Elongin B (about 18 kDa) and Elongin C (about 15 kDa) subunits. The Elongin BC subcomplex is the stable core that recruits BC-box proteins, and its interaction with the von Hippel-Lindau tumor suppressor protein has been characterized biochemically. Early reviews described the Elongin BC complex as a regulator of multiple cellular functions through these interactions.
Substrate recruitment for ubiquitination
In simple terms: Elongin C acts like a docking site that grabs target proteins so they can be tagged for destruction.
Elongin C within the Elongin BC subcomplex serves as the substrate-recognition module for Cullin-RING E3 ubiquitin ligases, binding BC-box proteins such as VHL and SOCS2. In hepatocellular carcinoma, SOCS2-enhanced ubiquitination of SLC7A11 depends on this elongin BC scaffold and promotes ferroptosis and radiosensitization. In melanoma, the Elongin BC complex negatively regulates AXL and marks a differentiated phenotype, demonstrating substrate-specific regulation.
Cooperative recognition in targeted degradation
In simple terms: Drugs called PROTACs can hijack the elongin complex to selectively destroy disease-causing proteins.
Structural studies of PROTAC cooperative recognition have revealed how chemical degraders recruit the Elongin BC complex for selective protein degradation. This mechanism exploits the same BC-box binding surface used by natural substrates such as VHL and SOCS2. The elongin complex therefore functions as both a physiological regulator and a therapeutic effector module.
Role in specialized contexts
In simple terms: The elongin complex also appears in tissue-specific processes such as sperm development.
A testis-specific E3 ubiquitin ligase complex governs spermiogenesis and male fertility, indicating that elongin-related BC-box modules operate in specialized developmental contexts. This extends the functional reach of GO:0070449 beyond canonical transcription elongation and cancer biology.
Key Genes Involved in GO:0070449 elongin complex
The following genes and proteins are the principal components and interactors of the elongin complex (GO:0070449) and its associated ubiquitin ligase pathways.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ELOA (Elongin A) | Transcriptionally active subunit of the elongin complex that suppresses RNA polymerase II pausing | Core component for structural and elongation studies |
| ELOB (Elongin B) | Small subunit (~18 kDa) that stabilizes the Elongin BC subcomplex | Essential scaffold for BC-box protein recruitment |
| ELOC (Elongin C) | Small subunit (~15 kDa) that binds BC-box proteins and Cullin-RING ligases | Central adaptor for ubiquitination and PROTAC action |
| VHL | BC-box protein that binds Elongin BC and acts as a tumor suppressor | Mutated in clear-cell renal cell carcinoma |
| SOCS2 | BC-box protein that uses elongin BC to ubiquitinate SLC7A11 | Promotes ferroptosis and radiosensitization in hepatocellular carcinoma |
| AXL | Receptor tyrosine kinase negatively regulated by the Elongin BC complex | Marks a differentiated phenotype in melanoma |
| SLC7A11 | Cystine transporter ubiquitinated via SOCS2 and elongin BC | Ferroptosis and radiosensitization target in hepatocellular carcinoma |
| CUL2 | Cullin scaffold of Cullin-RING ligases that partners with Elongin BC | Ubiquitin ligase assembly for VHL and SOCS2 substrates |
| RBX1 | RING finger protein of Cullin-RING ligases | Catalytic module for ubiquitin transfer |
| EPAS1 (HIF-2alpha) | Substrate of VHL-elongin BC ubiquitination in oxygen sensing | Implicated in clear-cell renal cell carcinoma |
| HIF1A | Substrate of VHL-elongin BC under hypoxia | Oxygen-sensing pathway linked to renal cancer |
| TCEB1 (ELOC alias) | Alternative symbol for Elongin C | Used in genetic and biochemical studies |
| TCEB2 (ELOB alias) | Alternative symbol for Elongin B | Used in genetic and biochemical studies |
| TCEB3 (ELOA alias) | Alternative symbol for Elongin A | Used in transcription elongation studies |
| SOCS-box proteins | Family of BC-box-containing adaptors | Diverse cellular functions through elongin BC |
| Testis-specific E3 ligase components | Specialized ubiquitin ligase complex for spermiogenesis | Male fertility and developmental biology |
How Is elongin complex Regulated?
The elongin complex is regulated at multiple levels. Its substrate specificity is determined by BC-box proteins such as VHL and SOCS2, which bind Elongin C and recruit distinct targets for ubiquitination. The Elongin BC complex negatively regulates AXL in melanoma, indicating that substrate availability and cellular context modulate its output. Structural studies show that PROTACs can cooperatively recruit the Elongin BC complex, revealing that its substrate-recognition surface is pharmacologically tunable. In specialized contexts, a testis-specific E3 ubiquitin ligase complex governs spermiogenesis, suggesting tissue-specific regulation of elongin-related modules. Early biochemical reviews emphasized that the Elongin BC complex regulates multiple cellular functions through its interchangeable substrate adaptors.
elongin complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| VHL | Clear-cell renal cell carcinoma | VHL knockout or point-mutation renal cell models |
| ELOC (Elongin C) | VHL pathway disruption in renal cancer | ELOC knockout or BC-box binding mutant knock-in |
| AXL | Melanoma differentiation and progression | ELOB/ELOC knockout melanoma cells with AXL readout |
| SOCS2 | Hepatocellular carcinoma ferroptosis and radiosensitization | SOCS2 overexpression or knockout HCC models |
| SLC7A11 | Ferroptosis regulation in hepatocellular carcinoma | SLC7A11 point-mutation or knockout cells |
Clear-cell renal cell carcinoma
The elongin BC complex binds the von Hippel-Lindau tumor suppressor protein, and disruption of this interaction is central to clear-cell renal cell carcinoma. Integrated molecular analysis of clear-cell renal cell carcinoma has identified VHL pathway alterations as a key feature of the disease. Because VHL uses Elongin C as its substrate-recognition module, mutations affecting this interface impair ubiquitination of HIF substrates and promote tumorigenesis.
Melanoma
The Elongin BC complex negatively regulates AXL and marks a differentiated phenotype in melanoma. This finding links GO:0070449 to melanoma cell state and suggests that elongin complex activity influences tumor progression and therapeutic response. AXL is a known receptor tyrosine kinase associated with invasive phenotypes, and its regulation by Elongin BC provides a mechanistic connection to disease.
Hepatocellular carcinoma and ferroptosis
SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma, and this process depends on the elongin BC scaffold. This places the elongin complex in the regulation of ferroptosis, a form of cell death relevant to cancer therapy. Targeting this axis may sensitize tumors to radiation through SLC7A11 degradation.
Male fertility and spermiogenesis
A testis-specific E3 ubiquitin ligase complex governs spermiogenesis and male fertility, indicating that elongin-related BC-box modules function in developmental contexts beyond cancer. This expands the disease relevance of GO:0070449 to reproductive biology.
From elongin complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of Elongin A affect RNA polymerase II pausing? | ELOA knockout cell line with nascent RNA sequencing |
| Does Elongin C BC-box binding mediate VHL substrate ubiquitination? | ELOC point-mutation knock-in disrupting BC-box binding |
| Does Elongin BC regulate AXL in melanoma? | ELOB or ELOC knockout melanoma cells with AXL protein readout |
| Does SOCS2-elongin BC promote SLC7A11 degradation? | SOCS2 overexpression and SLC7A11 knock-in tagged cells |
| Can PROTACs recruit Elongin BC for degradation? | Tagged knock-in of Elongin BC subunits with degradation assays |
| Is a testis-specific elongin-related ligase required for fertility? | Testis-specific E3 ligase knockout mouse model |
How to Study the elongin complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Cryo-EM | Three-dimensional structure of RNA polymerase II-Elongin complex | Mapping Elongin A-polymerase interfaces |
| Nascent RNA sequencing | RNA polymerase II pausing and elongation rates | Testing elongin complex function in transcription |
| RNA-seq | Global gene expression changes | Phenotyping elongin subunit perturbations |
| Ubiquitination assay | Substrate modification by Cullin-RING ligases | Testing BC-box protein function |
| Proteomics | Protein interaction and degradation profiles | Identifying elongin BC substrates and PROTAC targets |
| Immunoblotting | Steady-state protein levels of AXL, SLC7A11 | Validating degradation or stabilization |
| Cell viability and ferroptosis assays | Cell death and radiosensitization | Evaluating therapeutic response in HCC models |
| Mouse genetics | Fertility and spermiogenesis phenotypes | Testing testis-specific E3 ligase function |
Structural biology of the elongin complex
Cryo-electron microscopy and biochemical reconstitution have been used to determine the structure of the transcribing RNA polymerase II-Elongin complex, revealing how Elongin A engages the polymerase. Structural studies of PROTAC cooperative recognition have similarly resolved how chemical degraders recruit the Elongin BC complex. These approaches define the molecular interfaces that can be targeted by mutations or drugs.
Transcriptional and proteomic profiling
Because the elongin complex suppresses RNA polymerase II pausing, nascent RNA sequencing and RNA-seq can measure changes in elongation and gene expression upon subunit perturbation. Proteomic analysis of ubiquitination substrates can identify BC-box protein targets such as SLC7A11 and AXL. These methods connect GO:0070449 to downstream cellular phenotypes.
Ubiquitination and degradation assays
In vitro ubiquitination assays using Cullin-RING ligases and Elongin BC can test whether specific BC-box proteins promote substrate modification. Degradation assays with tagged substrates, including PROTAC-based systems, measure the functional output of elongin complex recruitment. These assays are essential for linking genotype to protein stability.
Disease-relevant functional models
Clear-cell renal cell carcinoma models with VHL pathway alterations are used to study elongin BC-dependent ubiquitination. Melanoma models with Elongin BC perturbation reveal AXL regulation and differentiation phenotypes. Hepatocellular carcinoma models with SOCS2 manipulation test ferroptosis and radiosensitization.
How CRISPR Can Be Used to Study GO:0070449 elongin complex
Knockout
CRISPR knockout of ELOA, ELOB, or ELOC can abolish elongin complex function and reveal its role in transcription elongation and ubiquitination. Knockout of ELOB or ELOC in melanoma cells can test whether Elongin BC negatively regulates AXL. Knockout of SOCS2 or SLC7A11 pathway components can dissect ferroptosis regulation in hepatocellular carcinoma.
Point Mutation
Point mutations in ELOC that disrupt BC-box binding can separate transcription elongation from ubiquitination functions. Disease-relevant VHL mutations that impair elongin BC interaction can be modeled to study clear-cell renal cell carcinoma. Point mutations in substrate proteins such as SLC7A11 can identify ubiquitination sites.
Knock-in
Tagged knock-in of Elongin A, B, or C enables affinity purification and structural studies of the complex. Knock-in of degradation tags on substrates such as AXL or SLC7A11 allows precise measurement of elongin BC-dependent turnover. Knock-in models of PROTAC targets can validate cooperative recognition mechanisms.
Overexpression
Overexpression of SOCS2 can enhance SLC7A11 ubiquitination and promote ferroptosis in hepatocellular carcinoma models. Overexpression of Elongin BC subunits can amplify substrate recruitment for biochemical assays. Overexpression of BC-box proteins can drive selective degradation of targets in PROTAC studies.
How EDITGENE Supports elongin complex Research
Researchers studying elongin complex-related genes often need to determine whether a candidate gene is causally involved in transcription elongation, substrate ubiquitination, or disease phenotypes. EDITGENE provides CRISPR-based cell models and screening services to interrogate GO:0070449 components and their interactors with precision.
Contact EDITGENE today to design your custom CRISPR model for elongin complex research.
Frequently Asked Questions About elongin complex
What is the elongin complex?
The elongin complex (GO:0070449) is a transcription elongation factor complex that suppresses RNA polymerase II pausing and consists of Elongin A, Elongin B, and Elongin C subunits.
What genes are involved in the elongin complex?
The core genes are ELOA (Elongin A), ELOB (Elongin B), and ELOC (Elongin C), with associated BC-box proteins such as VHL and SOCS2.
What is GO:0070449?
GO:0070449 is the Gene Ontology identifier for the elongin complex, a cellular component involved in transcription elongation and ubiquitin ligase substrate recognition.
How does the elongin complex regulate RNA polymerase II?
It suppresses RNA polymerase II pausing and may promote proper alignment of the 3'-end of nascent transcripts with the polymerase catalytic site.
What diseases are linked to the elongin complex?
It is linked to clear-cell renal cell carcinoma, melanoma, and hepatocellular carcinoma through VHL, AXL, and SOCS2 pathways.
How is the elongin complex used in PROTACs?
PROTACs recruit the Elongin BC complex for selective protein degradation, as shown by structural studies of cooperative recognition.
What is the Elongin BC complex?
The Elongin BC complex is the stable subcomplex of Elongin B and Elongin C that serves as a substrate-recognition module for Cullin-RING E3 ubiquitin ligases.
Does the elongin complex affect ferroptosis?
Yes, SOCS2-enhanced ubiquitination of SLC7A11 via elongin BC promotes ferroptosis and radiosensitization in hepatocellular carcinoma.
How can I study the elongin complex with CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models of ELOA, ELOB, ELOC, and substrates can dissect its functions.
Is the elongin complex involved in fertility?
A testis-specific E3 ubiquitin ligase complex governs spermiogenesis and male fertility, indicating elongin-related modules function in reproduction.
Conclusion
The elongin complex (GO:0070449) is a multifunctional cellular component that couples transcription elongation with ubiquitin-mediated proteolysis. Its Elongin A, B, and C subunits support RNA polymerase II processivity and provide a scaffold for BC-box proteins such as VHL and SOCS2, linking it to clear-cell renal cell carcinoma, melanoma, and hepatocellular carcinoma. Structural and chemical biology studies have further established the Elongin BC interface as a target for PROTAC-based degradation. Continued research using CRISPR models and multi-omics approaches will clarify how this complex coordinates transcription and protein turnover in health and disease.
References
- 1. Schieven SM et al.. 2023. The Elongin BC Complex Negatively Regulates AXL and Marks a Differentiated Phenotype in Melanoma.. Mol Cancer Res 21(5):428-443 PMID: 36753617
- 2. Chen Y et al.. 2023. Structure of the transcribing RNA polymerase II-Elongin complex.. Nat Struct Mol Biol 30(12):1925-1935 PMID: 37932450
- 3. Chen Q et al.. 2023. SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma.. Cell Death Differ 30(1):137-151 PMID: 35995846
- 4. Gadd MS et al.. 2017. Structural basis of PROTAC cooperative recognition for selective protein degradation.. Nat Chem Biol 13(5):514-521 PMID: 28288108
- 5. Conaway JW et al.. 1998. The Elongin BC complex and the von Hippel-Lindau tumor suppressor protein.. Biochim Biophys Acta 1377(2):M49-54 PMID: 9606976
- 6. Aso T. 1999. [Elongin BC complex as the regulator of multiple cellular functions].. Seikagaku 71(4):278-82 PMID: 10358440
- 7. Sato Y et al.. 2013. Integrated molecular analysis of clear-cell renal cell carcinoma.. Nat Genet 45(8):860-7 PMID: 23797736
- 8. Wu T et al.. 2026. A testis-specific E3 ubiquitin ligase complex governs spermiogenesis and male fertility.. Nat Commun 17(1) PMID: 41730923
